Biopharma dealmakers reflect on last year's shifts in the market, as they gear up for another 'active' year ahead
While 2021 was another big year for biopharma R&D — with the number of IPOs and biotech VC funding eclipsing last year …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
